Randomized Trialmoderate evidence

Mivocabtagene Autoleucel CD19 Chimeric Antigen Receptor T-Cell Therapy in Stiff Person Syndrome: A Nonrandomized Clinical Trial.

JAMA neurology·November 9, 2026·PMID 43002394

Why it matters

Stiff person syndrome is a disabling autoimmune neurologic disease with limited effective treatments. This trial provides evidence that CD19 CAR T-cell therapy can induce immunotherapy-free remissions with meaningful functional improvements, offering a potential disease-modifying option for patients refractory to standard immunomodulation.

Infographic summary of Mivocabtagene Autoleucel CD19 Chimeric Antigen Receptor T-Cell Therapy in Stiff Person Syndrome: A Nonrandomized Clinical Trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled